DualityBio and Genentech inked a major collaboration to develop antibody-drug conjugates built around DualityBio’s DUPAC payload platform. The deal includes $45 million upfront with potential milestone payments exceeding $1 billion across programs, and Genentech will take over later clinical development and commercialization. In financing activity, DualityBio’s Roche pact complements a separate Series C raise highlighted in the dataset for AusperBio’s chronic hepatitis B oligonucleotide program, which secured $120 million to push through phase 3 and beyond. For the industry, both transactions reflect continued investor and Big Pharma preference for platform-enabled payload innovation—particularly where resistance mechanisms and late-stage development paths are treated as part of the deal thesis.